In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Evaluation of modified valsalva maneuver in treatment of supraventricular tachycardia among adult patients presenting to ER

Session Poster session 1

Speaker Ahmed Youssef

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Supraventricular Tachycardia (non-AF) - Treatment
  • Session type : Poster Session
  • FP Number : P474

Authors : A Youssef (Ismailia,EG), M Omar (Ismailia,EG), G Nasr (Ismailia,EG), M Ali (Ismailia,EG), A Essa (Ismailia,EG)


A Youssef1 , M Omar1 , G Nasr1 , M Ali1 , A Essa1 , 1Suez Canal University - Ismailia - Egypt ,


Background: The valsalva maneuver (VM) is safe, guideline-recommended first line emergency treatment for supraventricular tachycardia (SVT), however it is performed inconsistently with low success rate. in addition the effect of patient repositioning during VM has not been well studied.

Purpose: To evaluate the effectiveness of modified VM in treatment of SVT among adult patients presenting to ER.

Methods: A randomized control trial enrolling sixty patients presenting to ER with SVT (excluding AF and atrial flutter). two groups; standard VM group (30 patients, group A) and modified VM (30 patients, group B). A standard strain against the rubber tube of sphygmomanometer to generate a pressure about 40 mmHg used to ensure that the VM other than the change in position was the same for both groups. in group A; the patient sit at 45 degrees and exhale into the tube for 1 minute. in group B; the patient sit at 45 degrees and exhale forcefully into the tube for 15 seconds, followed by supine repositioning and passive leg raising to 45 degrees for 15 seconds, then the patient returned to the semi-recumbent position for 30 seconds before reassessment of cardiac rhythm. If patient didn't restore sinus rhythm after one minute of VM, I.V verapamil was given.

Results: There was no statistical significant difference regarding baseline characteristics (age, sex, baseline heart rate or blood pressure or serum K level) between both groups. Thirty-eight (63%) were women. In group B, fourteen patients (46.7%) of 30 participants versus only six patients (20%) in group A achieved the primary outcome of sinus rhythm at 1 minute of VM (p value = 0.02). Regarding secondary outcomes; the use of emergency drugs for SVT termination (i.e calcium channel blocker), the requirement for verapamil after VM was significantly fewer in group B compared with group A (53% vs 80%, p value = 0.01).

Conclusion: A simple, cost-free, safe postural modification to the standard VM is interestingly effective, returning nearly half (47%) of patients presenting with SVT to sinus rhythm.

CCB dose

Group A (standard VM)

count (%)

Group B (modified VM)

count (%)

Half dose 3 (10.0%) 8 (26.5%)
Full dose 21 (70%) 8 (26.5)
Total 24 (80%) 16 (53.0%)
Use of Calcium channel blockers (CCB, i.e Verapamil) for restoration of sinus rhythm.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are